摘要
为提高原发性肝癌的诊断率和与肝硬化、其他慢性肝病的鉴别诊断,本文采用放射免疫分析法(RIA)和免疫放射分析法(IRMA)。对50例健康体检者、48例原发性肝癌、39例肝硬化、36例其他慢性肝病患者,分别检验其血清中甲胎蛋白(AFP),糖类抗原19-9(CA19-9)肿瘤标志物的含量,结果进行比较,发现原发性肝癌患者血清AFP、CA19-9含量显著增高,与对照组、肝硬化及其他慢性肝病组比较有显著差异(p<0.01)。血清AFP阳性检出率原发性肝癌组72.9％,肝硬化组43.5％,慢性肝病组13.5％。血清CA19-9阳性检出率,原发性肝癌63.7％,肝硬化48.7％,慢性肝病11％。本文检测各疾病组患者血清CA19-9时发现,原发性肝癌组与其他慢性肝病组比较有显著差异(p<0.01),肝硬化组与慢性肝病组比较有较明显差异(p<0.05)。慢性肝病组与对照组比较无差异(P>0.05)。结果提示CA19-9的测定有助于原发性肝癌与肝硬化、其他慢性肝病的诊断和鉴别诊断。在13例原发性肝癌AFP阴性者,血清CA19-9、11例阳性,阳性率84.6％符合文献报道。本文结果提示,血清AFP、CA19-9联合检测可以相互取长补短,减少假阴性,提高原发性肝癌阳性检出率和与肝硬化及慢性肝病在鉴别诊断上的临床实用价值。
In order to improve the accuracy of the diagnosis of primary liver cancer and the differential diagnosis from liver cirrhosis and other chronic liverdiseases, we tested serum specimens from 50 healthy subjects, 48 patients with primary liver cancer, 39 patients with cirrhosis and 36 patients with other chronic liver diseases for the content of the tumor markers AFP and CA19-9 with RIA and IRMA.The results showed that the levels of AFP and CA19-9 in patients with primary liver cancer were strikingly higher than those in ot.her groups (p<0.01). The positive rate of AFP in the cancer group was 72.9%, compared with 43.5% in cirrhosis anp 13.5% in other chronic liver diseases. The positive rate of CA19-9 was 68.7% in the cancer group, while in cirrhosis was 48.7% and in the group of other chronic liver diseases was 11%. The level of CA19-9 in the cancer group was signifticantly different from those in other grpups(p<0.01).The level in cirrhosis was also different from that in other chronic liver diseases (p<0.05); while there was almost no difference between the levels in chronic liver diseases and the controls(p>0.05). Thus testing of CA19-9 was helpful in the differential diagnosis of various liver diseases. Tn 13 cancer patients with negative AFP, serum CA19-9 was positive in 11 of them. The positive rate was 84.6%. being close to the document report. We believe that testing of serum AFP and CA19-9 is complementary to each other and is of practical diagnostic value.
出处
《放射免疫学杂志》
CAS
1997年第6期330-332,共3页
Journal of Radioimmanology
